Follow Us:
PARS‑TECTO PSMA® Kit
Sterile, NonPyrogen Lyophilized Powder
- Initial diagnosis and staging of prostate cancer
- Detection of prostate cancer recurrence or smaller lesions not visible by other methods such as CT or MRI
- Assistance in determining the extent of disease spread
- Evaluation of lymph node involvement and scattered metastases
- Assessment of bone metastases as the most common site of prostate cancer spread
- Assistance in physician decision‑making for treatment selection
- Evaluation of the effectiveness of prior therapies such as hormone therapy, chemotherapy, and others
The active substance TECTO PSMA is a small molecule (ligand) that targets and binds to receptors on the surface of prostate cancer cells. 99mTc‑Hynic PSMA is a developed radiopharmaceutical designed for imaging subtle changes in the biological and biochemical processes associated with disease progression. The expression of distinct proteins by diseased cells provides an opportunity for precise imaging of metastatic prostate cancer.
The TECTO PSMA kit is a suitable and more affordable option for regions without access to PET Scan imaging systems.
The PARS‑TECTO PSMA® kit is manufactured under aseptic conditions. After radiolabeling with a specified amount of sterile, non‑pyrogen sodium pertechnetate injection (Na99mTcO₄) — eluted from a 99Mo/99mTc generator — the preparation is ready for intravenous administration. The dose to be used will be prescribed by the physician.
Hynic PSMA (20 µg)
Stannous Chloride Dihydrate
Tricine
Mannitol
Ethylenediamineacetic Acid
- Store the PARS‑TECTO PSMA® kit in a freezer (-8°C to -20°C) and protected from light. The cold chain must be maintained under all circumstances.
- After radiolabeling, 99mTc‑Hynic PSMA remains stable for up to 4 hours at 15°C to 25°
- The PARS‑TECTO PSMA® kit should not be used after the expiration date.